AusperBio Therapeutics raised a $120 million Series C on Aug 27, 2026 to advance its lead hepatitis B candidate AHB-137 through a Phase 3 registrational program, backed by RA Capital, Qiming Venture Partners, CDH Investments and others. The round brings the company's total funding to $360 million since 2024.
Biotech capital is still flowing to late-stage clinical assets; healthtech founders can cite large milestone-driven Series C rounds like this when framing staged, data-gated raises for investors.
Source: Tech Startups
More that helps you.
Scan.com raises $220M to build a single-API US medical imaging network
Scan.com closed $220M on August 31, 2026: a $90M Series C equity round led by Noteus Partners plus $130M in debt facilities from VerisFi Capital and Atempo Growth. Revenue doubled…
Intrepid Growth closes US$525M debut fund to back AI founders
Toronto- and London-based Intrepid Growth Partners announced the final close of its inaugural fund at US$525 million (about C$730 million), US$25 million above target, on 14 Septem…
Hong Kong's Qupital secures $300M to fund e-commerce sellers with AI underwriting
Qupital announced roughly $300 million in combined equity and asset-backed financing on September 13, 2026, with M Capital leading and MUFG and Quester Capital participating. It pr…
Off-peak dining app First Table raises A$10M to expand across Australian cities
First Table, the discount off-peak restaurant booking platform now live in 22 Australian cities, raised A$10 million on 11 September 2026. Backers included existing investors Alter…
Get briefs like this tuned to you.
In the app, Founder Briefs are personalized to your country, industry and stage, and you can save the ones that matter.
See plans →